Mayo Clinic Researcher Dr. Matthew Goetz discusses the ACCRU Neoadjuvant Breast Cancer Trial (EVANGELINE)
Outcomes in cancer treatment depend on the most basic question: Did the patient take the drug? In a recent National Cancer Database analysis of breast cancer patients with hormone receptor breast cancer who had received neoadjuvant chemotherapy, Dr. Matthew Goetz, and his team discovered that upwards of 40% of patients never started endocrine therapy. Those who didn't take their adjuvant endocrine therapy had a 60 to 70% higher risk of death. In this episode with Dr. Goetz, who directs the Mayo Clinic Breast Cancer Specialized Program of Research Excellence (SPORE) and co-leads the Women's Cancer Program at the Mayo Clinic Comprehensive Cancer Center, he also discusses an innovative ACCRU neoadjuvant endocrine trial for premenopausal women with hormone receptor positive, HER2 negative breast cancer that recently activated. Podcast host Dr. Kristen Ciombor and Dr. Goetz also highlight the importance of community physicians in trial development and patient outcomes.
Create your
podcast in
minutes
It is Free